

# THE LANCET

## **Supplementary webappendix**

This webappendix formed part of the original submission and has been peer reviewed.  
We post it as supplied by the authors.

Supplement to: Levey AS, Coresh J. Chronic kidney disease. *Lancet* 2011; published  
online Aug 15. DOI:10.1016/S0140-6736(11)60178-5.

## Appendix 1. Further Reading: Clinical Practice Guidelines (Table 1, from reference 9)

### 1. Reducing the risk for developing CKD

- Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 2007 [cited 2010 October 7]; Available from: <http://www.sign.ac.uk/pdf/sign97.pdf>
- World Health Organization. Prevention of Cardiovascular Disease: Pocket Guidelines for Assessment and Management of Cardiovascular Risk. 2007 [cited 2010 October 7]; Available from: [http://www.who.int/cardiovascular\\_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf](http://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf)
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):S1-S201.
- Standards of medical care in diabetes--2008. Diabetes Care. 2008 Jan;31 Suppl 1:S12-54.
- New Zealand Guidelines Group (NZGG). Management of Type 2 Diabetes. 2003 [cited 2010 October 7]; Available from: [http://www.nzgg.org.nz/guidelines/0036/diabetes\\_full\\_text.pdf](http://www.nzgg.org.nz/guidelines/0036/diabetes_full_text.pdf)
- National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated August 2009. 2008 [cited 2010 October 7]; Available from: [http://www.heartfoundation.org.au/SiteCollectionDocuments/A\\_Hypert\\_Guidelines2008\\_2009Update\\_FINAL.pdf](http://www.heartfoundation.org.au/SiteCollectionDocuments/A_Hypert_Guidelines2008_2009Update_FINAL.pdf)
- Canadian Hypertension Education Program. 2008 CHEP Recommendations for the Management of Hypertension. 2008 [cited 2010 October 7]; Available from: [http://hypertension.ca/chep/wp-content/uploads/2008/03/2008-chepsipiral-booklet-final\\_jan28.pdf](http://hypertension.ca/chep/wp-content/uploads/2008/03/2008-chepsipiral-booklet-final_jan28.pdf)
- European Society of Hypertension. 2007 Guidelines for Management of Arterial Hypertension 2007 [cited 2010 October 7]; Available from: <http://www.eshonline.org/Guidelines/ArterialHypertension.aspx>
- Singapore Ministry of Health. Hypertension. 2005 [cited 2010 October 7]; Available from: [http://www.moh.gov.sg/mohcorp/uploadedfiles/Publications/Reports/2005/NHS\\_2004%28Part3%29.pdf](http://www.moh.gov.sg/mohcorp/uploadedfiles/Publications/Reports/2005/NHS_2004%28Part3%29.pdf)
- Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003 Nov;21(11):1983-92.
- Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec;42(6):1206-52.
- Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens. 2004 Mar;18(3):139-85.
- Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007 Jan;28(1):88-136.

### 2. Early detection of CKD

- Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. 2007 [cited 2010 October 7]; Available from: <http://www.sign.ac.uk/pdf/sign97.pdf>
- World Health Organization. Prevention of Cardiovascular Disease: Pocket Guidelines for Assessment and Management of Cardiovascular Risk. 2007 [cited 2010 October 7]; Available from: [http://www.who.int/cardiovascular\\_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf](http://www.who.int/cardiovascular_diseases/guidelines/PocketGL.ENGLISH.AFR-D-E.rev1.pdf)
- Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):S1-S201.
- Standards of medical care in diabetes--2008. Diabetes Care. 2008 Jan;31 Suppl 1:S12-54.
- New Zealand Guidelines Group (NZGG). Management of Type 2 Diabetes. 2003 [cited 2010 October 7]; Available from: [http://www.nzgg.org.nz/guidelines/0036/diabetes\\_full\\_text.pdf](http://www.nzgg.org.nz/guidelines/0036/diabetes_full_text.pdf)
- National Heart Foundation of Australia (National Blood Pressure and Vascular Disease Advisory Committee). Guide to management of hypertension 2008. Updated August 2009. 2008 [cited 2010 October 7]; Available from:

[http://www.heartfoundation.org.au/SiteCollectionDocuments/A\\_Hypert\\_Guidelines2008\\_2009Update\\_FINAL.pdf](http://www.heartfoundation.org.au/SiteCollectionDocuments/A_Hypert_Guidelines2008_2009Update_FINAL.pdf)

- Canadian Hypertension Education Program. 2008 CHEP Recommendations for the Management of Hypertension. 2008 [cited 2010 October 7]; Available from: [http://hypertension.ca/chep/wp-content/uploads/2008/03/2008-chepspiral-booklet-final\\_jan28.pdf](http://hypertension.ca/chep/wp-content/uploads/2008/03/2008-chepspiral-booklet-final_jan28.pdf)
  - European Society of Hypertension. 2007 Guidelines for Management of Arterial Hypertension 2007 [cited 2010 October 7]; Available from: <http://www.eshonline.org/Guidelines/ArterialHypertension.aspx>
  - Singapore Ministry of Health. Hypertension. 2005 [cited 2010 October 7]; Available from: [http://www.moh.gov.sg/mohcorp/uploadedfiles/Publications/Reports/2005/NHS\\_2004%28Part3%29.pdf](http://www.moh.gov.sg/mohcorp/uploadedfiles/Publications/Reports/2005/NHS_2004%28Part3%29.pdf)
  - Whitworth JA. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. *J Hypertens*. 2003 Nov;21(11):1983-92.
  - Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension*. 2003 Dec;42(6):1206-52.
  - Williams B, Poulter NR, Brown MJ, Davis M, McNnes GT, Potter JF, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. *J Hum Hypertens*. 2004 Mar;18(3):139-85.
  - Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). *Eur Heart J*. 2007 Jan;28(1):88-136.
  - National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2):S1-266. Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_ckd/toc.htm](http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm).
  - Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Evaluation of Renal Function. 2005 [cited 2010 September 27]; Available from: [http://www.cari.org.au/ckd\\_evaluation\\_function\\_list.php](http://www.cari.org.au/ckd_evaluation_function_list.php)
  - Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Urine Protein as Diagnostic Test. 2004 [cited 2010 September 27]; Available from: [http://www.cari.org.au/ckd\\_urineprot\\_list\\_pub2004.php](http://www.cari.org.au/ckd_urineprot_list_pub2004.php)
  - UK Renal Association. Clinical Practice Guidelines for the Care of Patients with Chronic Kidney Disease. 2007 [cited 2010 September 27]; 4:[Available from: <http://www.renal.org/Clinical/GuidelinesSection/CKD.aspx#Anchor-6296>
  - Brosius FC, 3rd, Hostetter TH, Kelepouris E, Mitsnefes MM, Moe SM, Moore MA, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease: a science advisory from the American Heart Association Kidney And Cardiovascular Disease Council; the Councils on High Blood Pressure Research, Cardiovascular Disease in the Young, and Epidemiology and Prevention; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: developed in collaboration with the National Kidney Foundation. *Circulation*. 2006 Sep 5;114(10):1083-7.
  - Rodbard HW, Blonde L, Braithwaite SS, Brett EM, Cobin RH, Handelsman Y, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. *Endocr Pract*. 2007 May-Jun;13 Suppl 1:1-68.
  - National Institute for Health and Clinical Excellence (NICE) National Collaborating Centre for Chronic Conditions. Chronic kidney disease. Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care. 2008 [cited 2010 October 7]; Available from: <http://www.nice.org.uk/nicemedia/live/12069/42119/42119.pdf>
3. Identifying the clinical diagnosis (cause and pathology)
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39(2):S1-266. Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_ckd/toc.htm](http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm).
  - Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Evaluation of Renal Function. 2005 [cited 2010 September 27]; Available from: [http://www.cari.org.au/ckd\\_evaluation\\_function\\_list.php](http://www.cari.org.au/ckd_evaluation_function_list.php)

- Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Urine Protein as Diagnostic Test. 2004 [cited 2010 September 27]; Available from: [http://www.cari.org.au/ckd\\_urineprot\\_list\\_pub2004.php](http://www.cari.org.au/ckd_urineprot_list_pub2004.php)
  - UK Renal Association. Clinical Practice Guidelines for the Care of Patients with Chronic Kidney Disease. 2007 [cited 2010 September 27]; 4:[Available from: <http://www.renal.org/Clinical/GuidelinesSection/CKD.aspx#Anchor-6296>
  - Canadian Society of Nephrology. Professional Practice Publications. Elevated Creatinine Referral Guidelines. 1999 [cited 2010 September 27]; Available from: <http://csnscn.ca/english/professional%20practice/programmes/default.asp?s=1>
  - European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant. 2002;17 Suppl 7:7-15.
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. 2007 [cited 2010 September 27]; Available from: [http://www.kidney.org/professionals/kdoqi/guideline\\_diabetes/](http://www.kidney.org/professionals/kdoqi/guideline_diabetes/)
  - National Institute for Health and Clinical Excellence (NICE) National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). 2008 [cited 2010 September 27]; Available from: <http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf>
4. Slowing the progression of CKD and reducing albuminuria
- UK Renal Association. Clinical Practice Guidelines for the Care of Patients with Chronic Kidney Disease. 2007 [cited 2010 September 27]; 4:[Available from: <http://www.renal.org/Clinical/GuidelinesSection/CKD.aspx#Anchor-6296>
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. 2007 [cited 2010 September 27]; Available from: [http://www.kidney.org/professionals/kdoqi/guideline\\_diabetes/](http://www.kidney.org/professionals/kdoqi/guideline_diabetes/)
  - National Institute for Health and Clinical Excellence (NICE) National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). 2008 [cited 2010 September 27]; Available from: <http://www.nice.org.uk/nicemedia/live/11983/40803/40803.pdf>
  - Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Prevention of Progression of Kidney Disease 2006 [cited 2010 September 27]; Available from: [http://www.cari.org.au/ckd\\_prevent\\_list\\_published.php](http://www.cari.org.au/ckd_prevent_list_published.php)
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease 2004 [cited 2010 September 27]; Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_bp/index.htm](http://www.kidney.org/professionals/kdoqi/guidelines_bp/index.htm)
5. Preventing complications of decreased GFR: Threats to patient safety
- UK Renal Association. Clinical Practice Guidelines for Acute Kidney Injury. 2008 [cited 2010 October 13]; Available from: <http://www.renal.org/Clinical/GuidelinesSection/AcuteKidneyInjury.aspx#downloads>
  - Aronoff G, Bennett W, Berns J, Brier M, Kasbekar N, Mueller B, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA American College of Physicians; 2007.
  - McCullough PA. Contrast-induced acute kidney injury. Journal of the American College of Cardiology. 2008 Apr 15;51(15):1419-28.
  - Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging. 2009 Dec;30(6):1357-63.
6. Preventing complications of decreased GFR: Uremic complications
- a. ESA and iron for anemia

- Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Biochemical and Haematological Targets. Haemoglobin. 2008 [cited 2010 September 27]; Available from: [http://www.cari.org.au/dialysis\\_bht\\_published.php](http://www.cari.org.au/dialysis_bht_published.php)
  - Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Biochemical and Haematological Targets. Iron. 2008 [cited 2010 September 27]; Available from: [http://www.cari.org.au/dialysis\\_bht\\_published.php](http://www.cari.org.au/dialysis_bht_published.php)
  - Canadian Society of Nephrology. Professional Practice Guidelines. CSN Clinical Practice Guidelines for Management of Anemia Associated with Chronic Kidney Disease. 2008 [cited 2010 September 27]; Available from: <http://csnscn.ca/english/professional%20practice/guidelines/default.asp?s=1>
  - Locatelli F, Aljama P, Barany P, Canaud B, Carrera F, Eckardt KU, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004 May;19 Suppl 2:ii1-47.
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease: 2007 Update of Hemoglobin Target. 2007 [cited 2010 October 7]; Available from: [http://www.kidney.org/professionals/KDOQI/guidelines\\_anemiaUP/index.htm](http://www.kidney.org/professionals/KDOQI/guidelines_anemiaUP/index.htm)
  - UK Renal Association. Complications of CKD. 2007 [cited 2010 September 30]; Available from: <http://www.renal.org/Clinical/GuidelinesSection/ComplicationsofCKD.aspx#downloads>
  - National Collaborating Centre for Chronic Conditions. Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. London: Royal College of Physicians; 2006.
- b. Vitamin D and phosphate binders for CKD-MBD
- KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international. 2009 Aug(113):S1-130.
- c. Appropriate energy intake for malnutrition
- The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). Clinical Practice Guidelines for Nutrition in Chronic Renal Failure 2000 [cited 2010 October 7]; Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_updates/doqi\\_nut.html](http://www.kidney.org/professionals/kdoqi/guidelines_updates/doqi_nut.html)
  - Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Nutrition and Growth in Kidney Disease. 2005 [cited 2010 September 28]; Available from: [http://www.cari.org.au/ckd\\_nutrition\\_list\\_published.php](http://www.cari.org.au/ckd_nutrition_list_published.php)
  - Fouque D, Vennegoor M, ter Wee P, Wanner C, Basci A, Canaud B, et al. EBPG guideline on nutrition. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii45-87.
  - UK Renal Association. Nutrition in CKD. 2010 [cited 2010 September 28]; Available from: <http://www.renal.org/Clinical/GuidelinesSection/NutritionInCKD.aspx#downloads>
- d. Referral to nephrologists
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2):S1-266. Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_ckd/toc.htm](http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm).
  - Canadian Society of Nephrology. Professional Practice Publications. Elevated Creatinine Referral Guidelines. 1999 [cited 2010 September 27]; Available from: <http://csnscn.ca/english/professional%20practice/programmes/default.asp?s=1>
  - European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant. 2002;17 Suppl 7:7-15.
  - Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Acceptance onto Dialysis. Timing of referral of chronic kidney disease patients to nephrology services (adult). 2010 [cited 2010 September 27]; Available from: [http://www.cari.org.au/dialysis\\_accept\\_published.php](http://www.cari.org.au/dialysis_accept_published.php)

## 7. Treating the nephrotic syndrome

- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2):S1-266. Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_ckd/toc.htm](http://www.kidney.org/professionals/kdoqi/guidelines_ckd/toc.htm).
  - Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Urine Protein as Diagnostic Test. 2004 [cited 2010 September 27]; Available from: [http://www.cari.org.au/ckd\\_urineprot\\_list\\_pub2004.php](http://www.cari.org.au/ckd_urineprot_list_pub2004.php)
8. Improving the outcomes of dialysis and transplantation
- a. Modality selection for dialysis
    - UK Renal Association. Clinical Practice Guidelines for the Care of Patients with Chronic Kidney Disease. 2007 [cited 2010 September 27]; 4:[Available from: <http://www.renal.org/Clinical/GuidelinesSection/CKD.aspx#Anchor-6296>
    - European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant. 2002;17 Suppl 7:7-15.
    - Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Acceptance onto Dialysis. Timing of referral of chronic kidney disease patients to nephrology services (adult). 2010 [cited 2010 September 27]; Available from: [http://www.cari.org.au/dialysis\\_accept\\_published.php](http://www.cari.org.au/dialysis_accept_published.php)
    - Churchill DN, Blake PG, Jindal KK, Toffelmire EB, Goldstein MB. Clinical practice guidelines for initiation of dialysis. Canadian Society of Nephrology. J Am Soc Nephrol. 1999 Jun;10 Suppl 13:S289-91.
    - UK Renal Association. Clinical Practice Guidelines for Haemodialysis. 2007 [cited 2010 September 28]; Available from: [http://www.renal.org/Clinical/GuidelinesSection/Haemodialysis.aspx#Access\\_Withdrawal](http://www.renal.org/Clinical/GuidelinesSection/Haemodialysis.aspx#Access_Withdrawal)
  - b. Access placement for hemodialysis
    - UK Renal Association. Clinical Practice Guidelines for Haemodialysis. 2007 [cited 2010 September 28]; Available from: [http://www.renal.org/Clinical/GuidelinesSection/Haemodialysis.aspx#Access\\_Withdrawal](http://www.renal.org/Clinical/GuidelinesSection/Haemodialysis.aspx#Access_Withdrawal)
    - Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Vascular Access. 2008 [cited 2010 September 28]; Available from: [http://www.cari.org.au/dialysis\\_va\\_list\\_published.php](http://www.cari.org.au/dialysis_va_list_published.php)
    - Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, et al. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-27.
    - European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section II. Haemodialysis adequacy. Nephrol Dial Transplant. 2002;17 Suppl 7:16-31.
    - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines for Vascular Access, Update 2006. 2006 [cited 2010 September 29]; Available from: [http://www.kidney.org/professionals/kdoqi/guideline\\_upHD\\_PD\\_VA/index.htm](http://www.kidney.org/professionals/kdoqi/guideline_upHD_PD_VA/index.htm)
  - c. Recipient selection for transplantation
    - EBPG (European Expert Group on Renal Transplantation); European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant. 2000;15 Suppl 7:1-85.
  - d. Donor selection for transplantation
    - EBPG (European Expert Group on Renal Transplantation); European Renal Association (ERA-EDTA); European Society for Organ Transplantation (ESOT). European Best Practice Guidelines for Renal Transplantation (part 1). Nephrol Dial Transplant. 2000;15 Suppl 7:1-85.
    - Caring for Australasians with Renal Impairment (CARI). Transplantation Guidelines. Living Kidney Donors. 2010 [cited 2010 September 29]; Available from: [http://www.cari.org.au/trans\\_living\\_donors\\_published.php](http://www.cari.org.au/trans_living_donors_published.php)
  - e. Adequate dialysis dose

- Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Vascular Access. 2008 [cited 2010 September 28]; Available from: [http://www.cari.org.au/dialysis\\_va\\_list\\_published.php](http://www.cari.org.au/dialysis_va_list_published.php)
  - European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section II. Haemodialysis adequacy. Nephrol Dial Transplant. 2002;17 Suppl 7:16-31.
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines for Vascular Access, Update 2006. 2006 [cited 2010 September 29]; Available from: [http://www.kidney.org/professionals/kdoqi/guideline\\_upHD\\_PD\\_VA/index.htm](http://www.kidney.org/professionals/kdoqi/guideline_upHD_PD_VA/index.htm)
  - Caring for Australasians with Renal Impairment (CARI). Dialysis Guidelines. Dialysis Adequacy. 2005 [cited 2010 September 29]; Available from: [http://www.cari.org.au/dialysis\\_adequacy\\_published.php](http://www.cari.org.au/dialysis_adequacy_published.php)
  - Dombros N, Dratwa M, Feriani M, Gokal R, Heimbürger O, Krediet R, et al. European best practice guidelines for peritoneal dialysis. 7 Adequacy of peritoneal dialysis. Nephrol Dial Transplant. 2005 Dec;20 Suppl 9:ix24-ix7.
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines For Peritoneal Dialysis Adequacy, Update 2006. 2006 [cited 2010 September 29]; Available from: [http://www.kidney.org/professionals/kdoqi/guideline\\_upHD\\_PD\\_VA/index.htm](http://www.kidney.org/professionals/kdoqi/guideline_upHD_PD_VA/index.htm)
  - UK Renal Association. Clinical Practice Guidelines for Peritoneal Dialysis in CKD. 2010 [cited 2010 September 28]; Available from: <http://www.renal.org/Clinical/GuidelinesSection/PeritonealDialysis.aspx#downloads>
  - UK Renal Association. Clinical Practice Guidelines for Peritoneal Access. 2010 [cited 2010 September 28]; Available from: <http://www.renal.org/Clinical/GuidelinesSection/PeritonealAccess.aspx>
- f. Improved immunosuppression for transplantation
- KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155.
- g. Complications associated with decreased GFR and albuminuria after transplantation<sup>57</sup>
- KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155.
9. Reducing the risk of CVD
- Caring for Australasians with Renal Impairment (CARI). Chronic Kidney Disease Guidelines. Cardiovascular Risk Factors. 2005 [cited 2010 September 29]; Available from: [http://www.cari.org.au/ckd\\_cardio\\_list\\_published.php](http://www.cari.org.au/ckd_cardio_list_published.php)
  - Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, et al. EBP guideline on haemodynamic instability. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii22-44.
  - European Best Practice Guidelines Expert Group on Hemodialysis. European Renal Association. Section VII. Vascular disease and risk factors. Nephrol Dial Transplant. 2002;17 Suppl 7:88-109.
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease 2006 [cited 2010 September 30]; Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_lipids/index.htm](http://www.kidney.org/professionals/kdoqi/guidelines_lipids/index.htm)
  - The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI™). KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. 2005 [cited 2010 September 30]; Available from: [http://www.kidney.org/professionals/kdoqi/guidelines\\_cvd/index.htm](http://www.kidney.org/professionals/kdoqi/guidelines_cvd/index.htm)
  - Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998 Nov;32(5):853-906.
  - Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Cullerton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003 Oct 28;108(17):2154-69.

- Ronco C, McCullough P, Anker SD, Anand I, Aspromonte N, Bagshaw SM, et al. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. *European heart journal*. 2010 Mar;31(6):703-11.

## Appendix 2. Further Reading: Clinical Trials for CKD (Table 2)

### ACE inhibition and ARB vs. other antihypertensive regimens

- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. *N Engl J Med.* 1993 Nov 11;329(20):1456-62.
- Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. *N Engl J Med.* 1996 Apr 11;334(15):939-45.
- Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. *Lancet.* 1998 Oct 17;352(9136):1252-6.
- Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. *Lancet.* 1999 Jul 31;354(9176):359-64.
- Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern Med.* 2001 Jul 17;135(2):73-87.
- Agodoa LY, Appel L, Bakris GL, Beck G, Bourgoignie J, Briggs JP, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. *JAMA.* 2001 Jun 6;285(21):2719-28.
- Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001 Sep 20;345(12):861-9.
- Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001 Sep 20;345(12):851-60.
- Wright JT, Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA.* 2002 Nov 20;288(19):2421-31.
- Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. *N Engl J Med.* 2001 Sep 20;345(12):870-8.
- Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT, Jr., Whelton PK, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *Arch Intern Med.* 2005 Apr 25;165(8):936-46.
- Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. *N Engl J Med.* 2006 Jan 12;354(2):131-40.
- Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet.* 2007 Sep 8;370(9590):829-40.
- Mann JF, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, et al. Effect of telmisartan on renal outcomes: a randomized trial. *Ann Intern Med.* 2009 Jul 7;151(1):1-10, W1-2.
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet.* 2000 Jan 22;355(9200):253-9.

### Lower vs. usual blood pressure target

- Wright JT, Jr., Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. *JAMA.* 2002 Nov 20;288(19):2421-31.
- Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. *N Engl J Med.* 1994 Mar 31;330(13):877-84.

- Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. *Ann Intern Med.* 2005 Mar 1;142(5):342-51.
- Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. *Lancet.* 2005 Mar 12-18;365(9463):939-46.
- Appel LJ, Wright JT, Jr., Greene T, Agodoa LY, Astor BC, Bakris GL, et al. Intensive blood-pressure control in hypertensive chronic kidney disease. *N Engl J Med.* 2010 Sep 2;363(10):918-29.
- Cushman WC, Evans GW, Byington RP, Goff DC, Jr., Grimm RH, Jr., Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *N Engl J Med.* 2010 Apr 29;362(17):1575-85.

#### More vs. less intensive glycemetic control in diabetes

- Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. *JAMA.* 2003 Oct 22;290(16):2159-67.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet.* 1998 Sep 12;352(9131):837-53.
- Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. *Diabetes Care.* 2000 Apr;23 Suppl 2:B21-9.
- Levin SR, Coburn JW, Abaira C, Henderson WG, Colwell JA, Emanuele NV, et al. Effect of intensive glycemetic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. *Diabetes Care.* 2000 Oct;23(10):1478-85.
- Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. *Lancet.* 2010 Aug 7;376(9739):419-30.
- Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008 Jun 12;358(24):2560-72.
- Duckworth W, Abaira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. *N Engl J Med.* 2009 Jan 8;360(2):129-39.

#### Low protein diet with or without amino acid or keto-acid supplements vs. usual protein diets

- Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. *Cochrane Database Syst Rev.* 2009(3):CD001892.

#### Statins vs. placebo

- Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: a meta-analysis. *J Am Soc Nephrol.* 2006 Jul;17(7):2006-16.
- [Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease \(Study of Heart and Renal Protection\): a randomised placebo-controlled trial. \*Lancet\* Published Online June 9, 2011](#)
- [Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, et al. The second United Kingdom Heart and Renal Protection \(UK HARP II\) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. \*Am J Kidney Dis.\* 2006 Mar;47\(3\):385-95.](#)
- Strippoli GF, Navaneethan SD, Johnson DW, Perkovic V, Pellegrini F, Nicolucci A, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. *BMJ.* 2008 Mar 22;336(7645):645-51.

#### Sodium bicarbonate vs. standard care

- de Brito-Ashurst I, Varaganam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am Soc Nephrol.* 2009 Sep;20(9):2075-84.

#### Paricalcitol vs. placebo

- Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. *Am J Kidney Dis.* 2009 Oct;54(4):647-52.

#### Somatostatin vs. placebo in PKD

- Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene-Iordache B, et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. *Kidney Int.* 2005 Jul;68(1):206-16.
- Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, et al. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. *J Am Soc Nephrol.* 2010 Jun;21(6):1052-61.

#### ☒mTOR inhibitors vs. placebo or standard care in PKD

- Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, et al. Everolimus in patients with autosomal dominant polycystic kidney disease. *New England Journal Medicine.* 2010 Aug 26;363(9):830-40.
- Serra AL, Poster D, Kistler AD, Krauer F, Raina S, Young J, et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. *New England Journal Medicine.* 2010 Aug 26;363(9):820-9.

#### ESA with higher vs. lower hemoglobin target

- Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med.* 2006 Nov 16;355(20):2085-98.
- Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med.* 2006 Nov 16;355(20):2071-84.
- Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med.* 1998 Aug 27;339(9):584-90.
- Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. *J Am Soc Nephrol.* 2005 Jul;16(7):2180-9.
- Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. *Lancet.* 2007 Feb 3;369(9559):381-8.
- Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. *Ann Intern Med.* 2010 Jul 6;153(1):23-33.

#### ESA vs. placebo

- Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med.* 2009 Nov 19;361(21):2019-32.

#### Vitamin D or analogues vs. other agents

- Coyne D, Acharya M, Qiu P, Abboud H, Battle D, Rosansky S, et al. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. *Am J Kidney Dis.* 2006 Feb;47(2):263-76.
- Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, Sprague SM, et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. *Am J Kidney Dis.* 2004 May;43(5):877-90.
- Nordal KP, Dahl E. Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. *J Clin Endocrinol Metab.* 1988 Nov;67(5):929-36.
- Kooienga L, Fried L, Scragg R, Kendrick J, Smits G, Chonchol M. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. *Am J Kidney Dis.* 2009 Mar;53(3):408-16.
- Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, Jordans JG, et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. *BMJ.* 1995 Feb 11;310(6976):358-63.

#### Cinacalcet vs. other agents

- Block GA, Zeig S, Sugihara J, Chertow GM, Chi EM, Turner SA, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. *Nephrol Dial Transplant*. 2008 Jul;23(7):2311-8.
- Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. *J Am Soc Nephrol*. 2004 Aug;15(8):2208-18.
- Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. *Kidney Int*. 2005 Oct;68(4):1793-800.
- Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. *J Am Soc Nephrol*. 2005 Mar;16(3):800-7.
- Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. *Kidney Int*. 2005 Feb;67(2):760-71.
- Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. *Clin Nephrol*. 2008 Apr;69(4):269-78.

#### Sevelamer vs. calcium-containing phosphorus binders

- Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. *Kidney Int*. 2007 Nov;72(9):1130-7.
- Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int*. 2002;62(1):245-52.
- Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int*. 2005 Oct;68(4):1815-24.
- Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. *Kidney Int*. 2007 Nov;72(10):1255-61.
- Qunibi W, Moustafa M, Muenz LR, He DY, Kessler PD, Diaz-Buxo JA, et al. A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renegel Evaluation-2 (CARE-2) study. *Am J Kidney Dis*. 2008 Jun;51(6):952-65.
- Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Phosphate binder impact on bone remodeling and coronary calcification--results from the BRiC study. *Nephron Clin Pract*. 2008;110(4):c273-83.
- St Peter WL, Liu J, Weinhandl E, Fan Q. A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: a secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. *Am J Kidney Dis*. 2008 Mar;51(3):445-54.

#### Early vs. usual initiation of dialysis

- Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled trial of early versus late initiation of dialysis. *N Engl J Med*. 2010 Aug 12;363(7):609-19.

#### Higher vs. lower dialysis dose

- Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*. 2002 Dec 19;347(25):2010-9.
- Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. *J Am Soc Nephrol*. 2002 May;13(5):1307-20.

#### Higher vs. lower dialysis membrane flux

- Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med*. 2002 Dec 19;347(25):2010-9.

#### Short daily (6 days per week) vs. usual (3 days per week) hemodialysis

- The FHN Trial Group, Chertow GM, Levin NW, Beck GJ, Depner TA, Eggers PW, Gassman JJ, et al. In-center hemodialysis six times per week versus three times per week. *N Engl J Med.* 2010 Dec 9;363(24):2287-300.

#### Antihypertensive agents vs. placebo or conventional agents

- Heerspink HJ, Ninomiya T, Zoungas S, de Zeeuw D, Grobbee DE, Jardine MJ, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. *Lancet.* 2009 Mar 21;373(9668):1009-15.

#### Statins vs. placebo

- Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *New England Journal Medicine.* 2005 Jul 21;353(3):238-48.
- Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. *New England Journal Medicine.* 2009 Apr 2;360(14):1395-407.
- Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet Published Online June 9, 2011*

#### Folic acid and B-vitamins vs. placebo

- Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. *JAMA.* 2007 Sep 12;298(10):1163-70.

#### Tacrolimus vs. cyclosporine

- Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. *Cochrane Database Syst Rev.* 2005(4):CD003961.

#### Anti-lymphocyte antibodies and low-dose calcineurin inhibitor vs standard dose calcineurin inhibitor for induction

- Ekberg H, Tedesco-Silva H, Demirbas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. *New England Journal Medicine.* 2007 Dec 20;357(25):2562-75.

#### Mycophenolate mofetil vs. placebo or azathioprine

- Knight SR, Russell NK, Barcena L, Morris PJ. Mycophenolate mofetil decreases acute rejection and may improve graft survival in renal transplant recipients when compared with azathioprine: a systematic review. *Transplantation.* 2009 Mar 27;87(6):785-94.
- Remuzzi G, Cravedi P, Costantini M, Lesti M, Ganeva M, Gherardi G, et al. Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. *J Am Soc Nephrol.* 2007 Jun;18(6):1973-85.
- Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. *Transplantation.* 1997 Jan 15;63(1):39-47.

#### mTOR inhibitors vs. calcineurin inhibitors

- Dantal J, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. *Transpl Int.* 2010 May 24.

#### Co-stimulatory blockade (beta1acept) vs. calcineurin inhibitors

- Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blanco G, et al. Costimulation blockade with belatacept in renal transplantation. *New England Journal Medicine.* 2005 Aug 25;353(8):770-81.

- Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). *Am J Transplant*. 2010 Mar;10(3):535-46.
- Vincenti F, Blanco G, Durrbach A, Friend P, Grinyo J, Halloran PF, et al. Five-year safety and efficacy of belatacept in renal transplantation. *J Am Soc Nephrol*. 2010 Sep;21(9):1587-96.